KRAS and breast neoplasm: The outcome of ISRIB's selective effect on ERO1 KO MDAMB231* breast tumours with up‐regulated PERK pathway is in line with other reports of the effectiveness of ISRIB on mutant KRAS lung cancer with high PERK/p‐eIF2alpha (Ghaddar et al., 2021; Jewer et al., 2020).